Summary
Danaher Corporation reported a 3.0% decrease in overall revenues for the second quarter of 2024 compared to the prior year, with core sales down 3.5%. This decline was primarily driven by weaker performance in the Biotechnology and Life Sciences segments, particularly in high-growth markets like China. Conversely, the Diagnostics segment showed resilience with increased core sales, led by North America. The company's net earnings from continuing operations also saw a year-over-year decrease, reflecting lower sales and increased other expenses. Despite the revenue headwinds, Danaher's gross profit margin improved due to lower cost of sales and the benefit from the Abcam acquisition. For the first six months of 2024, the trend of declining revenues and core sales continued, mirroring the quarterly performance. Operating profit margins across segments showed mixed results, with significant decreases in Life Sciences and Biotechnology, while Diagnostics saw substantial improvement. The company generated strong operating cash flows but utilized a significant portion for substantial stock repurchases during the period. Danaher maintained its focus on strategic investments and managing its capital structure, with liquidity expected to remain sufficient.
Financial Highlights
50 data points| Revenue | $5.74B |
| Cost of Revenue | $2.31B |
| Gross Profit | $3.43B |
| R&D Expenses | $391.00M |
| SG&A Expenses | $1.87B |
| Operating Income | $1.17B |
| Net Income | $907.00M |
| EPS (Basic) | $1.23 |
| EPS (Diluted) | $1.22 |
| Shares Outstanding (Basic) | 737.60M |
| Shares Outstanding (Diluted) | 742.40M |
Key Highlights
- 1Overall revenues decreased by 3.0% year-over-year for the second quarter of 2024, with core sales down 3.5%, driven by weaknesses in Biotechnology and Life Sciences segments.
- 2The Diagnostics segment demonstrated strength, with total sales up 1.5% and core sales up 3.0% in Q2 2024, driven by clinical diagnostics businesses.
- 3Net earnings from continuing operations decreased to $907 million ($1.22/share) in Q2 2024 from $920 million ($1.24/share) in Q2 2023, attributed to lower core sales and increased expenses.
- 4Gross profit margin improved to 59.7% in Q2 2024 from 56.1% in Q2 2023, benefiting from lower cost of sales and the Abcam acquisition.
- 5Operating cash flow from continuing operations was $3.2 billion for the first six months of 2024, a decrease of 9% year-over-year.
- 6Significant capital deployment was noted, with $4.5 billion spent on share repurchases in the first six months of 2024, alongside $0.4 billion in dividend payments.
- 7The company highlights ongoing strategic investments and its robust liquidity position, expecting sufficient cash flow to fund operations, acquisitions, and shareholder returns.